DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Reduces Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 39.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,036 shares of the company's stock after selling 2,619 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in IDEXX Laboratories were worth $1,669,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $412,258,000. Flossbach Von Storch SE lifted its stake in shares of IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after purchasing an additional 464,791 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in IDEXX Laboratories during the fourth quarter worth $156,412,000. William Blair Investment Management LLC boosted its stake in IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after buying an additional 316,048 shares during the period. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IDXX has been the subject of several recent analyst reports. Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Morgan Stanley upped their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $524.75.

IDEXX Laboratories Stock Up 0.1%

Shares of IDXX stock traded up $0.29 on Wednesday, hitting $509.42. The stock had a trading volume of 552,624 shares, compared to its average volume of 650,337. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business has a 50 day moving average price of $426.36 and a 200 day moving average price of $429.96. The company has a market cap of $40.97 billion, a PE ratio of 47.74, a P/E/G ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.71 earnings per share. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.